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ORIGINAL ARTICLE
Next-gen sequencing identiﬁes non-coding variation disrupting
miRNA-binding sites in neurological disorders
P Devanna1, XS Chen2, J Ho1,2, D Gajewski1, SD Smith3, A Gialluisi2,4, C Francks2,5, SE Fisher2,5, DF Newbury6,7 and SC Vernes1,5
Understanding the genetic factors underlying neurodevelopmental and neuropsychiatric disorders is a major challenge given their
prevalence and potential severity for quality of life. While large-scale genomic screens have made major advances in this area, for
many disorders the genetic underpinnings are complex and poorly understood. To date the ﬁeld has focused predominantly on
protein coding variation, but given the importance of tightly controlled gene expression for normal brain development and
disorder, variation that affects non-coding regulatory regions of the genome is likely to play an important role in these phenotypes.
Herein we show the importance of 3 prime untranslated region (3'UTR) non-coding regulatory variants across neurodevelopmental
and neuropsychiatric disorders. We devised a pipeline for identifying and functionally validating putatively pathogenic variants
from next generation sequencing (NGS) data. We applied this pipeline to a cohort of children with severe speciﬁc language
impairment (SLI) and identiﬁed a functional, SLI-associated variant affecting gene regulation in cells and post-mortem human brain.
This variant and the affected gene (ARHGEF39) represent new putative risk factors for SLI. Furthermore, we identiﬁed 3′UTR
regulatory variants across autism, schizophrenia and bipolar disorder NGS cohorts demonstrating their impact on
neurodevelopmental and neuropsychiatric disorders. Our ﬁndings show the importance of investigating non-coding regulatory
variants when determining risk factors contributing to neurodevelopmental and neuropsychiatric disorders. In the future,
integration of such regulatory variation with protein coding changes will be essential for uncovering the genetic causes of complex
neurological disorders and the fundamental mechanisms underlying health and disease.
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INTRODUCTION
Neuropsychiatric and neurodevelopmental disorders affect more
than 15% of the population1 and span a range of complex pheno-
types including schizophrenia (SCZ), autism spectrum disorder
(ASD), intellectual disability, bipolar disorder, attention deﬁcit
hyperactivity disorder (ADHD), and language/communicative
impairments. Great strides have been made in understanding
the genetic factors contributing to these disorders by screening
large cohorts of affected individuals using next generation
sequencing (NGS) approaches such as whole-exome sequencing
(WES) and more recently, whole-genome sequencing (WGS).
However, for many neuropsychiatric disorders, the underlying
genetic causes can be convoluted sometimes involving rare
variation across a large number of causative genes, small
contributions from common variants or no clear genetic causes
despite high heritability of the disorder. As such, neuropsychiatric
and neurodevelopmental disorders currently suffer from a high
degree of missing heritability that demands new and different
approaches when attempting to identify and assess genetic
variation that could contribute to these disorders.
WES has been a recent method of choice for uncovering causes
of neuropsychiatric disorders such as intellectual disability and
ASD2–5 due to its ability to rapidly and cheaply survey the protein
coding portions of the genome. However, by design WES only
surveys around 1% of the total genome sequence meaning that
the majority of genomic variation in each individual cannot be
assessed via this method. The importance of surveying non-
protein coding DNA—which makes up ~ 99% of the human
genome—is becoming apparent with the growing popularity of
WGS studies. WGS has now successfully been used to identify hot-
spots in the genome that are particularly susceptible to de novo
mutations,6 mutation parent-of-origin effects,7 novel genes under-
lying intellectual disability8 and the prevalence of disruptions of
non-coding regulatory regions in autistic individuals.9–11 These
studies make it clear that we must take the contribution of non-
coding variation seriously if we are to fully understand the
genetics of neuropsychiatric and neurodevelopmental disorders.
Within non-coding regions of the human genome, regulatory
elements such as promoters, enhancers and untranslated regions
are strong candidate regions for pathogenic variation because
they direct how much, when and where a gene is expressed.
Variation in regulatory regions such as single nucleotide variants
(SNV’s) or small indels, as well as larger scale copy number variants
have all been shown to signiﬁcantly affect gene expression.12–15
Regulatory variants that result in signiﬁcantly reduced gene
expression could mimic loss of function coding mutations.
Conversely, given that for many genes too much expression or
expression at the wrong place or time can be as detrimental as
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gene loss, mutations that increase gene expression or change its
timing/location can also contribute to disorder.13,16,17 Altered
gene expression patterns are a common feature of neuropsychia-
tric disorders such as ASD and SCZ and in some cases these
changes in gene expression can be linked directly to genomic/
pathogenic variation.12,18–20 This evidence points to a strong link
between aberrant gene expression and neurological disorders,
suggesting that variants in non-coding regulatory elements are
excellent candidates to ﬁll in some of the missing heritability of
neuropsychiatric and neurodevelopmental disorders.
To this end, we chose to investigate non-coding variation in an
NGS cohort, focusing speciﬁcally on a well-characterised regula-
tory region that strongly inﬂuences gene expression: the 3 prime
untranslated region (3′UTR). 3′UTRs of genes have long been
considered likely candidates for pathogenic mutations21–24 and
have been implicated in a range of neurological disorders.
Sequencing of genes involved in tinnitus, Parkinson’s disease,
Tourette’s syndrome and ASD have linked common single-
nucleotide polymorphisms (SNPs) and rare variants in 3′UTR
regions to these disorders.17,23–25 In addition, a number of key
considerations make these regions strong candidates for patho-
genicity and highly amenable to study. First, 3′UTR regions are
found at the end of all protein coding genes in the genome and
are comprehensively annotated26 making their identiﬁcation
routine. Second, 3′UTR regions directly affect the amount of
protein produced from a gene transcript via interactions with
small regulatory RNA molecules known as microRNAs. Because
these microRNA interactions are based on complementary
nucleotide pairing with short sequences (7–20 bp) in the
3′UTR regions, they can be accurately predicted from sequence
data in a high throughput manner. Finally, the functional effects of
observed variants can be tested in the lab using simple, scalable
assays. Functional testing to show that putative causative variants
have cellular consequences is crucial for determining pathogeni-
city of both coding and non-coding variation and the potential
scalability of these assays makes testing microRNA binding site
(MBS) variants particularly attractive for large-scale NGS studies.
Given all these factors, we designed an approach for using NGS
data to identify and functionally test the effects of variation in the
3′UTRome. Herein we show the efﬁcacy of this method using WES
data from a cohort of children classiﬁed as having a neurodeve-
lopmental disorder: speciﬁc language impairment (SLI). SLI, the
failure to acquire age appropriate language skills in the absence of
any explanatory factors (e.g. intellectual disability), affects up to
8% of school age children.27,28 Despite strong evidence for genetic
underpinnings of language impairment, efforts to identify
causative factors via linkage and association studies have found
multiple genomic regions, all predicted to have small effects.29–31
Thus, like many other neurodevelopmental disorders, SLI seems to
have a heterogeneous set of genetic risk factors contributing to
the phenotype. We used WES data from a cohort of 43 affected
children with severe SLI32 to demonstrate that it is possible to
identify putative causative variants in non-coding 3′UTR regions
using NGS data sets. Importantly we showed that variants can
have direct functional consequences for gene expression by
affecting miRNA binding sites, making them strong candidates for
pathogenicity. To show the wider relevance of this class of
variation we demonstrated that non-coding 3′UTR variants that
disrupt miRNA binding sites are found across a range of
neurological phenotypes, emphasising their potential relevance
to neuropsychiatric and neurodevelopmental disorders.
MATERIALS AND METHODS
Variant identiﬁcation in SLI cohort
Full methods on WES sequencing and variant calling are described by
Chen et al.32 Brieﬂy, for sequencing, the exome was captured by SureSelect
Human All Exon version-2 50 Mb kit (Agilent, Santa Clara, CA, USA),
sequenced using the SOLiD series 5500xl DNA sequencing platform (Life
Technologies, Carlsbad, CA, USA) and called via the standard BWA-GATK
pipeline, followed by quality ﬁltering as described by Chen et al.32 Ethical
agreement and informed consent from participants were obtained as
described previously.29
Genome-wide coordinates (hg19) for MBSs were downloaded from the
Targetscan 6.2 database.33 To identify WES variants that were overlapping
with these microRNA sites we used the BEDTools intersectBED function.34
Data availability
The primary data for the Chen et al.32 SLI exome study are deposited at The
Language Archive (TLA: https://corpus1.mpi.nl/ds/asv/?0), a public data
archive hosted by the Max Planck Institute for Psycholinguistics. Data are
stored at the TLA under the node ID: MPI2010433#, and accessible with a
persistent identiﬁer: https://hdl.handle.net/1839/00-0000-0000-001E-AD41-
2@view. Access can be granted upon request. TLA content is also visible
from the Data Archiving and Networked Services (DANS) database, the
Dutch national organization for sustained access to digital research data.
Cloning of constructs for functional assays
To generate the microRNA expression constructs for miR-215, -342 and
-346, regions encoding the primary transcripts were PCR ampliﬁed using
the primers listed in Supplementary Table S3 ('miRNAs'). The PCR products
were then cloned using AgeI and EcoRI restriction sites in the pLKO.1
expression vector (Invitrogen, Carlsbad, CA, USA) and the sequences were
conﬁrmed by Sanger sequencing.
miR-433 was initially cloned in the same way, but this construct did not
express functional miR-433 when tested in cells (data not shown). As such
an alternative approach was undertaken. MicroRNA primary transcripts
have been successfully used to drive expression of synthetic short hairpin
RNA (shRNA) to facilitate gene knockdown.35 In such hybrid constructs, the
sequence of the shRNA replaces the sequence that creates the stem–loop
of the endogenous miR. Because we knew that miR-342 was successfully
expressed (Supplementary Figure S1C), we inserted the stem–loop of
miR-433 (which is responsible for generating the mature miR-433
sequence) into a plasmid already containing an expression cassette for
miR-342. To facilitate removal of the miR-342 stem–loop from the miR-342
expression vector unique XbaI and SalI restriction sites were engineered at
the 5′ and 3′ (respectively) of the miR-342 stem–loop. The miR-433 stem–
loop was ampliﬁed using primers containing XbaI and SalI restriction sites
(detailed in Supplementary Table S3) and the PCR product was cloned in
place of the miR-342 stem–loop using XbaI and SalI. The sequence was
conﬁrmed via Sanger sequencing. Expression and functionality of this mir-
433 construct was conﬁrmed in a 'positive control' reporter assay (see
below; Supplementary Figure S1A).
'Positive control' reporter constructs were used to conﬁrm that all cloned
microRNAs were expressed and able to regulate gene expression by
interacting with ideal target sites in a reporter assay (Supplementary
Figure S1). Positive control reporters were generated as described
previously.36,37 Brieﬂy, oligonucleotides containing two high-sensitivity
binding sites for the cognate miRNAs were designed. To clone the reporter
cassettes, sense and antisense oligonucleotides were generated and
annealed to each other to form overhangs compatible with KﬂI restriction
sites—allowing directional cloning into compatible sites. Oligonucleotides
used for the generation of the reporters are listed in Supplementary Table
S3 ('miRNA positive control reporters').
The 3′UTR regions for each candidate gene spanning the patient
identiﬁed variants (approximately 300–400 bp; see Figure 3a) were cloned
into the pGL4.24 luciferase expression vector (Promega, Madison, WI, USA)
as reporter constructs. Control human genomic DNA (Novagen, EMD
Millipore, Billerica, MA, USA) was used to PCR amplify the regions of
interest (using the primers in Supplementary Table S3; '3′UTR'). The
sequences were conﬁrmed via Sanger sequencing and shown to contain
the control/reference allele. PCR products were cloned downstream of the
luciferase reporter gene using XbaI and FseI restriction sites. Vectors
carrying the alternative allele or with a deletion of the MBS were generated
using the QuickChange Site-Directed Mutagenesis kit (Agilent Techno-
logies) following the manufacturer's instructions and using the primers in
Supplementary Table S3 ('3′UTR SDM'). The presence of the desired
changes was conﬁrmed via Sanger sequencing.
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Cell culture and transfection
We performed the reporter assays in human HEK293 cells and for
comparison in a mouse neuronal cell line: Neuro2A (N2A) cells. Cell lines
were obtained from ATCC (LGC Standards, Teddington, UK) and are
routinely screened for mycoplasma contamination. Both cell lines are a
suitable cellular model as they are easy to culture and reach very high
transfection efﬁciency. The protein machinery that microRNAs use to
regulate gene expression is ubiquitous and we and others have previously
shown that this machinery is functional across different cell types.36,38–40
All the experiments were carried out using cells grown in Dulbecco's
modiﬁed Eagle's medium (Invitrogen) media supplemented with 10% fetal
calf serum (Sigma-Aldrich, St Louis, MO, USA) and 2 mM penicillin/
streptomycin. Cells were kept for the entire length of the experiments at
37 °C in the presence of 5% CO2. Transfections were performed using
GeneJuice (Novagen) following the manufacturer's instructions.
Luciferase assay
3.0 × 104 cells were seeded in each well of a 24-well plate (60–70%
conﬂuence) 24 h before transfection. Reporter constructs were co-
transfected into cells alongside the microRNA expression vector and a
Renilla reporter (pRL-TK) for internal normalisation. Forty-eight hours post-
transfection, ﬁreﬂy luciferase and Renilla luciferase activities were
measured as per the manufacturer's instructions (Dual Luciferase reporter
assay system; Promega).
Western blotting
3.0 × 105 HEK293 cells were seeded in each well of a six-well plate (60–70%
conﬂuence) 24 h prior to transfection of the microRNA (miR-215)
expression vector (4 μg). Forty-eight hours post-transfection, cells were
lysed in lysis buffer (0.1 M Tris, 150 mM NaCl, 10 mM EDTA, 0.2% Triton
X-100, 1% PMSF, protease inhibitor cocktail) at 4 °C for 10 min and
centrifuged at 10 000 g for 30 min at 4 °C, allowing cell debris to be
pelleted and discarded. Western blotting was performed as described
previously.41 Proteins were detected using primary antibodies for 60 min
at room temperature or at 4 °C overnight. Secondary antibodies were
applied for 30–60 min at room temperature. Antibodies were used as
follows: ARHGEF39 (rabbit polyclonal, catalogue #131551, manufacturer
NovoPro Bioscience, Shanghai, China) at 1/2000 concentration, B-actin
(mouse monoclonal, catalogue #A5441, manufacturer Sigma-Aldrich) at
1/2000 concentration, secondary anti-mouse HRP-conjugated antibody
(goat, catalogue #1706516, Bio-Rad Laboratories, Hercules, CA, USA) at
1/5000 concentration and secondary anti-rabbit HRP-conjugated antibody
(donkey polyclonal, catalogue #16284, Abcam, Cambridge, UK) at 1/5000
concentration. Densitometry was performed using the Imagelab 5.2.1 (Bio-
Rad) program to calculate arbitrary units reﬂecting relative protein
expression levels for ARHGEF39 and β-actin.
eQTL association studies
We utilised the Genotype-Tissue Expression project portal (GTEx) (http://
www.gtexportal.org; GTEx Analysis Release V6p) to determine associations
between individual SNPs and the expression of their corresponding
protein coding genes. We assessed genes for single-tissue eQTL values and
generated the multi-tissue eQTL comparison plot using the online ‘Gene
Association’ tool. Plots for individual brain regions were generated using
the ‘Test your own’ tool. Descriptions of the association and statistical
analyses generated by GTEx can be found in the relevant references.42,43
P-values are calculated for single-tissue associations and given that
associations were generated for 44 tissues, using a stringent multiple
testing correction (Bonferroni), P-values must be Po1.13e-3 to be
considered signiﬁcant.
Variant identiﬁcation in further NGS cohorts
We searched Pubmed for original research articles reporting human whole-
genome or whole-exome data. Articles were selected that interrogated
large cohorts related to neurodevelopmental and/or neuropsychiatric
disorders, as well as parent-of-origin effects. Data sets could only be
included for which variant call ﬁles including variants and genomic
coordinates were made available online. The reported statistics from each
research article were used to determine the number of potentially protein
altering variants and classify these variants as exonic, frameshift, missense
or nonsense changes. To determine the number of variants in MBSs, we
used the BEDTools intersectBED function34 to overlap genomic coordinates
of all reported variants with the genomic coordinates of all MBSs obtained
from the Targetscan 6.2 database.33
RESULTS
3′UTR variants within MBSs can be identiﬁed from WES data
We designed a pipeline to identify and assess the functionality of
both common and rare SNVs identiﬁed in non-coding 3′UTR
regions of the genome and applied this to a WES data set
from a cohort of 43 children with severe SLI32 (Figure 1). Chen
et al.32 identiﬁed all SNVs present in the WES data throughout the
genome. To rule out likely false positives, only SNVs with 410x
Figure 1. Workﬂow for identiﬁcation of non-coding 3′UTRome
variants in next generation sequencing (NGS) data. This ﬂowchart
demonstrates how variants can be identiﬁed in non-coding
regulatory regions of the genome using NGS data. First, a list of
all variants found within the 3′UTR regions of any genes was
generated from WES data (N= 6606). This was overlapped with all
predicted microRNA-binding sites in the genome (via targetscan 6.2)
(N= 54 199) to create a list of variants that lie within miRNA binding
sites in the 3′UTR of known genes (N= 8). The identiﬁed variants fell
into two categories; three rare variants found in a single proband
and ﬁve common variants that were annotated in dbSNP. Common
variants were further assessed using candidate SNP analysis in a
GWAS study of a large SLI cohort. One of the common variants
showed association with a quantitative measure of language
impairment. SNVs that pass the bioinformatic screening (N= 4) are
characterised using reporter assays to demonstrate functionality of
the wild-type site and consequences of patient identiﬁed variants.
For each stage the number of variants/sites identiﬁed in each
category in our SLI study is shown in brackets. 3'UTR, 3 prime
untranslated region; GWAS, genome-wide association study; SLI,
speciﬁc language impairment; SNP, single-nucleotide polymorphism;
SNV, single-nucleotide variant; WES, whole-exome sequencing.
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Figure 2. Identiﬁcation of non-coding variants in exome sequencing data. (a) Average read depth proﬁle across the 3′UTRome in the SLI WES
data set. On average, we reached 410 × coverage for the ﬁrst ~200 bp of the 3′UTR of a gene. For some genes, high coverage extended
beyond this boundary, allowing variants to be called further along the 3′UTR region. (b) Distribution of all predicted microRNA-binding sites
across the human 3′UTRome. In total, 54 199 miRNA-binding sites were predicted by Targetscan. These sites were mapped to their respective
genomic positions, showing that 8127 sites were located within the ﬁrst 200 bp of a 3′UTR region. This means that ~ 15% of all predicted
miRNA-binding sites are located within the ﬁrst 200 bp of the 3′UTR. This represents the region with the highest density of miRNA-binding
sites in the 3′UTRome and is also the region for which we have sufﬁcient depth of sequencing in the exome data to reliably call variation
(see dotted red lines). 3'UTR, 3 prime untranslated region; SLI, speciﬁc language impairment; WES, whole-exome sequencing.
Table 1. SNVs located within predicted microRNA-binding sites in SLI probands
Chr Position dbSNP dbSNP Global MAF freq Ref Alt Probands Gene microRNA
6 26469054 — — G Ca 1 BTN2A1 miR-342
13 25457299 — — G Ta 1 CENPJ miR-433
22 30421860 — — C Ta 1 MTMR3 miR-346
9 35661943 rs72727021 0.0469 A Ca 9 ARHGEF39 miR-192/215
16 87436764 rs1054528 NA Aa G 42 MAP1LC3B miR-204/211
16 79245820 rs383362 0.3223 G Ta 34 WWOX miR-134/758
19 6751293 rs1049232 0.2404 T Ga 13 TRIP10 miR-17-5p
19 53086946 rs190191374 0.0030 G Ta 1 ZNF701 miR-199/199-5p
Abbreviations: SLI, speciﬁc language impairment; SNP, single-nucleotide polymorphism; SNV, single-nucleotide variant. aMinor allele.
Figure 3. Functional consequences of 3′UTR variants identiﬁed in SLI exomes. (a) 3′UTR fragments of BTN2A1, CENPJ, MTMR3 and ARHGEF39
that spanned the predicted microRNA-binding sites were cloned downstream of the bioluminescent luciferase reporter gene. Schematic
illustrates the length of the 3′UTR (depicted by a straight line) relative to the end of the protein coding sequence of each gene (depicted by a
white box), the cloned fragments that was used in reporter assays, and the identity and position of the 3′UTR variants identiﬁed in the SLI
cohort. (b) Luciferase reporter assays were used to demonstrate if predicted binding sites were functionally regulated by the predicted
microRNAs. Candidate 3′UTR regions (shown in part a) were cloned downstream of the luciferase reporter gene. These UTR reporter
constructs (3′UTR: +) were co-expressed with the microRNA that was predicted to regulate each UTR. To determine speciﬁcity of this
regulation, control reporters were also tested that lacked any cloned fragment (3′UTR: − ). Expression of the reporter gene was the same with
(+) or without (− ) the 3′UTR fragment for BTN2A1, CENPJ and MTMR3, showing that these sites were not regulated by these microRNAs
(miR-342, miR-433 and miR-346). In contrast, reporter gene expression was signiﬁcantly lower when the ARHGEF39 3′UTR fragment was
present (+) compared to the reporter without any 3′UTR (− ), showing that miR-215 represses gene expression by interacting with the 3′UTR
when the reference allele 'A' is present. No differences in reporter activity were observed in the absence of miR-215 co-expression (data not
shown). (c) miR-215 regulates endogenous ARHGEF39. Cells transfected with the miR-215 vector (miR-215; +) displayed lower expression of
endogenous ARHGEF39 than mock-transfected cells (miR-215; − ), shown via western blotting. β-Actin was used as a loading control. Full scans
of blots with ladders to indicate band size are given in Supplementary Figure S4. (d) Quantiﬁcation of western blot data shown in part (c). The
relative expression of ARHGEF39 (normalised to β-actin) was calculated via densitometry and indicates signiﬁcant repression of endogenous
protein when miR-215 is present. (e) To determine if the presence of the alternative 'C' allele disrupts this regulatory relationship, we
introduced the 'C' allele into the reporter gene 3′UTR. The presence of the SLI-associated 'C' allele abolished repression of the reporter gene
by miR-215, showing its biological relevance. To show speciﬁcity of this effect the entire miR-215-binding site was deleted from the ARHGEF39
3′UTR reporter ('DEL') and this construct was also not regulated by miR-215. Deleting the entire miR-215 binding site ('DEL') was not
signiﬁcantly different to the effect of introducing the 'C' allele and neither of these were signiﬁcantly different from the construct that had no
3′UTR cloned fragment present ('3′UTR − '). Signiﬁcant differences between groups were calculated using an ANOVA test followed by post hoc
Tukey calculation. Only statistically signiﬁcant differences are noted. Signiﬁcance is indicated by *Po0.05 and **Po0.01. All results are
reported as the average± s.d. of three biological replicates. 3′UTR, 3 prime untranslated region; SLI, speciﬁc language impairment.
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sequence coverage were retained (see Supplementary Table S1 for
SNV numbers identiﬁed in different regions of the genome in this
data set). From all ﬁltered variants we extracted only those SNVs
that were within the 3′UTR region of a gene (N= 6606, over 4651
3′UTR regions) from these data. For the majority of 3′UTRs in the
genome (62.7% of 3′UTRs annotated by Ref-Seq), the ﬁrst ~ 200 bp
had a read depth ⩾ 10 allowing the reliable identiﬁcation of
variants in this region (Figure 2a). The highest density of MBSs is
also found in this initial region of the 3′UTR (Figure 2b), suggesting
that a large number of binding sites can be assessed per gene,
even using the limited region of the 3′UTR covered by standard
exome sequencing.
To determine if any of the 3′UTR variants fell within MBSs, we
separately searched for all predicted sites using the TargetScan
algorithm33 and overlaid these with the WES identiﬁed SNVs. Eight
3′UTR SNVs were thus identiﬁed within a sequence predicted to
be bound by a microRNA. Three of these were rare variants, only
found in a single individual and each in the 3′UTR of different
genes: BTN2A1, CENPJ and MTMR3 (Table 1). These were
considered to be private mutations as they were not present in
other data sets (dbSNP,44 1000 genomes,45 ExAc browser46),
indicating that they have a population frequency of less than
0.00082%. The presence of these rare variants in each of the
relevant probands was conﬁrmed with bi-directional Sanger
Functional non-coding variants in neurological disorders
P Devanna et al
5
Molecular Psychiatry (2017), 1 – 10
sequencing (Supplementary Figure S2). Five of these SNVs were
identiﬁed from dbSNP as SNPs found in the general population
(frequency 40.1%); four are common (population fre-
quency41%) and one is rare (0.3%) (Table 1).
A common variant within an MBS is associated with SLI
To determine the relevance of the common (SNP) variants to SLI
we took advantage of genome-wide SNP data from the SLI
Consortium (SLIC) sample. This data set comprised 285 SLI families
recruited from ﬁve centres across the UK; The Newcomen Centre
at Guy’s Hospital, London (now called Evelina Children’s Hospital);
the Cambridge Language and Speech Project (CLASP); the Child
Life and Health Department at the University of Edinburgh; the
Department of Child Health at the University of Aberdeen; and the
Manchester Language Study.29,31 The 43 probands sequenced
herein are a subset of this cohort. Two common SNPs (rs1054528
and rs190191374) were not genotyped in the SLIC (SLI Con-
sortium) data set and thus could not be assessed. However, three
of the ﬁve common SNPs were directly genotyped or imputed
from the SLIC data set (rs72727021 (imputed), rs383362 (geno-
typed) and rs1049232 (genotyped)) and thus we could use these
data for a candidate association analysis. Genotype data were
available for 983 parents and children from these 285 SLI families.
As previously described, various quantitative measures of
language-related abilities were available for children in this
cohort.29,47,48 Measures of expressive (ELS) and receptive (RLS)
language were obtained using the Clinical Evaluations of
Language Fundamentals (CELF-R).49 Verbal IQ (VIQ) and perfor-
mance IQ (PIQ) were assessed using the Wechsler Intelligence
Scale for Children50 and reading and spelling ability were
measured with the Wechsler Objective Reading Dimensions
(WORD).51 In addition, the phonological short-term memory of
adults and children was assessed with a 28-item test of non-word
Figure 4. rs72727021 is associated with ARHGEF39 expression in the human brain. (a) A multi-tissue eQTL comparison was made for
rs72727021 and ARHGEF39 using the GTEx database gene association tool across 44 tissue types. For each tissue is shown: the number of
RNA-Seq samples with genotype (‘Samples’), the effect size (‘Beta’), the signiﬁcance for that tissue (‘P-value’) and the posterior probability
likelihood that an effect exists in each tissue in the cross-tissue meta-analysis (‘post-prob’). Tissues are listed by effect size and those with a
post-prob40.9 and P-value below Po1.13e-3 (to account for multiple testing correction) are considered likely to have an effect in that tissue
and be signiﬁcantly associated. (b) The three tissues with the most signiﬁcant associations also had the highest effect sizes and all were found
in the brain. Rank normalised gene expression for each of these tissues; frontal cortex (BA9), cortex and cerebellum are shown, plotting
expression for each individual/sample with their corresponding genotype. In these three tissues, ARHGEF39 expression is higher when the
rs72727021 alternative allele ('C') is present in the heterozygous (‘CA’) or homozygous (‘CC’) state.
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repetition.52 Association was assessed within and between family
units using the QFAM test in PLINK. This quantitative test of
association employs an adaptive permutation procedure to
account for the dependence between related individuals. One
SNP (rs72727021), located in the 3′UTR of the ARHGEF39 gene
(also known as C9orf100), was associated with the non-word
repetition measure in the SLI cohort (empirical P= 7.7 × 10− 3)
(Supplementary Table S2). The alternative ‘C’ allele of rs72727021,
which has a population frequency of 4.7% (10.8% in 120 CEPH
individuals in 1000 genomes pilot phase I), is carried by 23% of the
SLIC probands (MAF= 12.3%) and is associated with a reduction of
10 points (0.66 s.d.) on the non-word repetition test in these
individuals.
We sought to ﬁnd supportive evidence for the association
between rs72727021 and non-word repetition in other data sets;
however, to our knowledge a replication data set does not exist.
We nonetheless queried the association in two independent data
sets: the Avon Longitudinal Study of Parents and Children
(ALSPAC) cohort53 and the Colorado Learning Disabilities Research
Centre (CLDRC) data set.54 Although no signiﬁcant association was
found in these data sets, a lack of support from these cohorts may
reﬂect variations in sample ascertainment since the SLIC popula-
tion was speciﬁcally selected for severe language phenotypes, or
the differences in tests used to generate the language ability
metrics. Further investigations in speciﬁcally selected samples will
be needed to clarify the genetic association between rs72727021
and language phenotypes.
Functional validation of a WES 3′UTR variant located within an
MBS
From our exome data we have identiﬁed four candidate variants
located in MBSs that may be related to the SLI phenotype: one
common variant (rs72727021) that is associated with non-word
repetition in the SLI cohort and three rare (private) variants.
Because these MBSs were identiﬁed via in silico predictions, we
ﬁrst set out to functionally validate the predicted interaction
between these 3′UTR-binding sites and their cognate microRNAs
using a reporter assay. We cloned an approx. 300–400 bp region
from each genes 3′UTR, spanning the predicted miRNA-binding
site (Figure 3a). This was inserted into an expression vector
downstream of the luciferase reporter gene as part of its 3′UTR.
We then determined the ability of the relevant microRNAs to
regulate the predicted binding site within the 3′UTR of each gene.
The binding sites identiﬁed within the 3′UTRs of BTN2A1, CENPJ
and MTMR3 were not regulated by their predicted microRNAs
(miR-342, miR-433 and miR-346, respectively) in these reporter
assays, suggesting they are not functional binding sites
(Figure 3b). As such we conclude that the rare variants found
within these binding sites are unlikely to disrupt microRNA-3′UTR
interactions, and thus unlikely to directly contribute to SLI via this
regulatory mechanism. However, 3′UTRs can have other functions,
and as such we cannot rule out that the presence of these variants
might affect other 3′UTR-dependent post-transcriptional pro-
cesses and lead to SLI-related phenotypic outcomes.
The binding site within the 3′UTR of ARHGEF39 is predicted to
be recognised and bound by both miR-215 and miR-192. The seed
sequence for these microRNAs are identical and both microRNAs
have the same conﬁdence score (as predicted by Targetscan),
suggesting that they are equally able to bind this site. Given this
equivalence, we used miR-215 to demonstrate the functionality of
this site. The ARHGEF39 3′UTR reporter containing the reference
allele of the rs72727021 SNP was signiﬁcantly downregulated by
miR-215 (Figure 3b). miR-215 was also able to signiﬁcantly repress
the expression of endogenous ARHGEF39 as demonstrated via
western blotting (Figures 3c and d). These data demonstrate that
the MBS found in the 3′UTR of ARHGEF39 is functional, and thatT
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miR-215 downregulates expression by interacting with this site
when the reference 'A' allele is present.
We then went on to determine how the presence of the SLI-
associated alternative 'C' allele affected this regulatory relation-
ship. Introducing the alternative 'C' allele into the 3′UTR of the
reporter construct abolished regulation by miR-215 (Figure 3e). To
conﬁrm the speciﬁcity of this interaction we also made a variant
where the miR-215-binding site in the 3′UTR was completely
deleted. As expected miR-215 could no longer regulate the
reporter construct when the deletion was introduced (Figure 3e).
Interestingly this loss of regulation was not signiﬁcantly different
to the control vector (lacking a 3′UTR) or the vector carrying the
alternative 'C' allele of rs72727021 in its 3′UTR. To conﬁrm that this
regulation also occurred in a neuronal cell line and was not a cell-
type-speciﬁc effect, we also performed these assays in Neuro2A
cells and saw equivalent results (see Supplementary Figure S3).
Together this demonstrates that the ARHGEF39 3′UTR can be
downregulated by miR-215 when the rs72727021 reference allele
‘A’ is present. If the SLI-associated 'C' allele is present, miR-215
regulation is abolished leading to higher expression, and this
effect is as severe as a complete deletion of the miR-215-
binding site.
In vivo brain expression differences are associated with
rs72727021
In addition to these functional assays, we also identiﬁed strong
support for the relevance of this variant in controlling ARHGEF39
expression levels in vivo. We interrogated eQTL data from the
GTEx portal55 across all 44 tissue/cell types present in the database
(Figure 4a) and found that the rs72727021 SNP was signiﬁcantly
associated with ARHGEF39 expression in the human brain.
Individuals that were heterozygous or homozygous for the
alternative ‘C’ allele had signiﬁcantly higher ARHGEF39 expression
in regions of the brain (cortex P= 6.3e-5; frontal cortex P= 9.8e-6;
cerebellum P= 4.3e-4) (Figure 4b). This mirrors the loss of
repression (higher reporter gene expression) we observed when
the alternative 'C' allele was present (compared with the reference
'A' allele) during in vitro functional assays (Figure 3e). To support
the speciﬁcity of this in vivo data we checked the GTEx portal for
eQTL effects related to the other four common variants identiﬁed
in this cohort (Table 1). No signiﬁcant differences in expression
were observed for these variants in the human brain, further
supporting the signiﬁcance of our ﬁndings.
Taken together, these ﬁndings show that we have identiﬁed a
common non-coding SNP with a signiﬁcant association to SLI and
a functional effect on gene expression in both cell models and the
human brain. We believe these data represent the ﬁrst time an
SLI-associated SNP has been reported to have direct functional
consequences.
Wider relevance of 3′UTRome variation to neurodevelopmental/
neuropsychiatric disorders
Herein we designed and tested an approach that would allow the
identiﬁcation and functional validation of 3′UTRome variants from
NGS data. We tested this approach using a cohort of language
impaired children given the complex genetic underpinnings of
this disorder. To illustrate the potential relevance of this approach
for wider neurodevelopmental and neuropsychiatric disorders, we
chose a selection of recent NGS studies searching for pathogenic
or de novo variation in large cohorts and for which variant call ﬁles
were made available online. These studies included whole-exome
and WGS data sets from cohorts of bipolar disorder, SCZ, ASD and
a study investigating parent-of-origin signatures of de novo
mutations.2,7,9,11,56,57 We determined the number of variants in
3′UTR regions that altered MBSs via intersection of these variants
with Targetscan coordinates (as described above) and identiﬁed
37 MBS variants in total. In all studies tested at least one MBS
variant was found, and up to 12 de novo variants could be
identiﬁed per cohort (Table 2).
DISCUSSION
Herein we demonstrate an approach for identifying and validating
the functionality of non-coding variants from NGS data. We used
this approach to identify a non-coding SNP in an MBS that is
associated with SLI and has functional consequences for gene
expression. We also demonstrated the presence of such 3′UTR-
MBS variants in wider cohorts of neuropsychiatric disorders
including SCZ, ASD and bipolar disorder.
This work represents the ﬁrst report of functional effects for a
non-coding SNP associated with SLI and highlights a possible role
for the rs72727021 variant and/or the ARHGEF39 gene (in which
the variant is found) in language disorder. Little is currently known
regarding the ARHGEF39 gene, but it is a member of the ARHGEF
family of Rho guanine nucleotide exchange factors. These proteins
act as molecular switches to regulate diverse processes including
transcriptional regulation, cell migration, cell growth and dendritic
development.58–60 Other members of this family have previously
been implicated in language impairment (ARHGEF19),29intellectual
disability (ARHGEF6)61 and moderate intellectual disability with
speech delay (ARHGEF9).4 Future studies into the expression
pattern and function of this gene may reveal a potential role for
ARHGEF39 in the development of language relevant circuitry in
the brain.
Given the importance of non-coding DNA for regulating gene
expression and the straightforward approach we propose for
assessing these variants, we strongly recommend that analysis of
3′UTRome MBS variation be included routinely for all NGS data/
pipelines. Although (by design) current WES platforms do not
sequence the entire 3′UTR, we have shown that we can extract
functional variants from exome sequence data using our SLI
cohort. Furthermore, we have shown that other existing WES data
sets investigating SCZ and ASD contain de novo variants in MBSs
that may contribute to the aetiology of these neuropsychiatric
disorders (Table 2). To date, it is estimated that more than one
million exomes have been sequenced using WES. The methodol-
ogy we propose here is immediately applicable to any of these
existing WES data sets for which raw sequence reads or called
variants are available. The widespread availability of WES data
makes it a cost-effective and practical way to discover functionally
relevant non-coding SNVs related to these neurological
phenotypes.
Studies of complex disorders are increasingly making use of
WGS, and including our pipeline when assessing WGS data from
large cohorts will allow unprecedented identiﬁcation of functional,
non-coding risk factors. In the WGS data sets we surveyed
(Table 2) even when cohorts were relatively small,11,56 selection
criteria were conservative (for example, only allowing de novo
variants to be included2,7,9,11,57), or when variants were only
included from a small number of candidate genes,56 at least one
3′UTR-MBS variant was identiﬁed per cohort, suggesting that this
class of variants will be highly prevalent across WGS studies.
Further supporting the relevance of these variants to phenotypes,
the MBS variants we identiﬁed in these cohorts were often located
in the 3′UTRs of genes previously implicated in their respective
disorders. For example, in the bipolar cohort four MBS variants
across six probands were identiﬁed in a leading candidate gene,
ANK3.56 In ASD cohorts, MBS variants were identiﬁed in BRD12 and
CHD2,9 both of which have been previously linked to autism via
identiﬁcation of putatively pathogenic de novo protein-coding
mutations and copy number variants.62–64 Indeed, taken together,
these ﬁndings argue for examination of the 3′UTR regions of
candidate genes across a range of disorders within existing NGS
data sets. Our ﬁndings suggest it is likely that new 3′UTR-MBS
variants will be identiﬁed via this approach that may help to
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explain some of the missing heritability of neurodevelopmental/
neuropsychiatric disorders.
NGS has brought astonishingly rapid advances in the high
throughput identiﬁcation of variants related to phenotypes.
Unfortunately our ability to determine which variants have
functional consequences has not kept pace. Yet, if a genetic
variant does not have molecular consequences for a gene or a cell,
it is unlikely that it will be causative or pathogenic, making
functional analysis crucial. Algorithms are widely used to predict
functional/pathogenic consequences; however, these have very
high false-positive/negative rates65,66 reinforcing the importance
of functional testing when attempting to link genetic variation to
phenotypes. A major strength of our approach is that it provides a
simple, high throughput method for validating the functional,
molecular consequences of non-coding 3′UTRome variants.
Because the functionality of a microRNA-3′UTR interaction can
be determined via a simple set of reporter gene assays in any cell
model, this approach facilitates high throughput and reliable
assessment of the consequences of identiﬁed 3′UTR variants.
In summary, we report an accessible, rapid and biologically
relevant method for assessing non-coding variation that adds
signiﬁcantly to our ability to identify causative variants from NGS
data—a major challenge facing the future of genomics. Neurop-
sychiatric disorders suffer from a high degree of missing
heritability and one of the ways we can address this issue is to
look beyond a ‘protein-centric’ view of the genome and also
address the relevance of non-coding variation. Adding this simple
pipeline to the standard WES/WGS toolkit is expected to reveal a
wealth of functional variation in largely overlooked non-coding
regions of the genome and will help to identify new links between
genes and disorders. Furthermore, by not stopping at identiﬁca-
tion but performing rigorous functional characterisation of the
molecular consequences of these variants, we will shed new light
on not only the causes of neurological disorders but the
fundamental molecular mechanisms underlying health and
disease.
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